Switching to second-generation tyrosine kinase inhibitor improves the response and outcome of frontline imatinib-treated patients with chronic myeloid leukemia with more than 10% of BCR-ABL/ABL ratio at 3 months
![Thumbnail](/xmlui/themes/Mirage2//images/thumbnails/thumn_cientif.png)
Identifiers![](/xmlui/themes/Mirage2//images/despl_identif.png)
Identifiers
Date issued
2015Type of content
Artigo
![](/xmlui/themes/Mirage2//images/final_lines.png)